Investors ditch Biota on BARDA laninamivir 'stop-work' order
This article was originally published in Scrip
Shares of Biota Pharmaceuticals spiraled down more than 37% on 29 April the Biomedical Advanced Research and Development Authority (BARDA) issued a stop-work order notifying the company to discontinue work on laninamivir octanoate, pending a decision about the outcome of a recently completed in-process review (IPR) of the firm's contract.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.